Association of Serum Eotaxin Levels and Markers of Myocardiac Injury in Hemodialysis Patients

NCT06211244 | Completed

• 1 other identifier: 112062
• Study Type: observational
• Target: 291
• Locations: 1 country
• Sites: 1

Brief Summary

Background: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality among dialysis patients. Eotaxin-1(also known as Eotaxin and CCL11), an eosinophil-specific chemoattractant that plays a role in a variety of pathologic conditions including allergy, coronary heart disease, and inflammatory bowel disease. CCL11 has been shown to be overexpressed in human atherosclerotic lesions. Moreover, eotaxin-1 levels are higher in non-uremic coronary artery disease patients than in healthy individuals. Methods: The study will enrolled 400 hemodialysis patients. Patients are diagnosed with coronary artery disease based on clinical presentation and confirmed by angiography. Serum eotaxin-1 and 8-isoprostane levels are determined by enzyme-linked immunosorbent assay (ELISA). High-sensitivity cTnI immunoassays and albumin redox state by high-performance liquid chromatography are used for measurements. Aim: In this study, we aimed to determine the eotaxin-1 concentrations of patients with coronary artery disease and to investigate the role of eotaxin-1 and markers of myocardial injury.

Conditions

Myocardium; Injury; Coronary Artery Disease

Keywords

coronary artery disease; Eotaxin-1; hemodialysis patients; myocardial injury

Outcome Measures

Primary Outcomes (1)

• Analysis of biomarkers of serum eotaxin levels.

  Eotaxin levels and the serum levels of markers of myocardial injury as well as oxidative stress in a group of prevalent hemodialysis patients.

  1 years

Secondary Outcomes (5)

• Redox state of serum albumin assays

  1 years

• Analysis of biomarkers of MCP-1

  1 years

• Analysis of biomarkers of IL-6

  1 years

• Analysis of biomarkers of 8-isoprostane

  1 years

• Analysis of biomarkers of High Sensitivity Troponin I

  1 years

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

patients have to be at least 20-years-old and on outpatient hemodialysis (HD) for at least 3 months.

You may qualify if:

• Both sexes aged 20 years or over
• Received stable hemodialysis at least 3 months.
• Written informed consent.

You may not qualify if:

• acute infection or malignancy

Sponsors & Collaborators

• Tungs' Taichung Metroharbour Hospital: lead

Study Sites (1)

Tungs' Taichung MetroHarbour Hospital

Taichung, Taiwan

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

Wounds and Injuries; Coronary Artery Disease

Condition Hierarchy (Ancestors)

Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Study Officials

• Paik Seong Lim, PhD

  Tungs' Taichung Metroharbour Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 8, 2024
• First Posted: January 18, 2024
• Study Start: May 2, 2024
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: June 6, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)